Good decisions require good information
Find hidden gems and smart strategies from top experts when you join Seeking Alpha.
DXCM DexCom, Inc.Stock Price & Overview
$118.77
Charts
Quant Ranking
DXCM Analysis
DXCM News
Latest Headlines
Ratings Summary
People Also Follow
Similar to DXCM
ETFs Holding DXCM
DXCM Company Profile
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
DXCM Revenue
DXCM Earnings Per Share
Earnings Estimates
Earnings Revisions
Valuation
Growth
Profitability
Momentum
Capital Structure
Dividends
DXCM Ownership
DXCM Peers
Risk
Technicals
DXCM Transcripts
Investor Presentations
DXCM SEC Filings
Press Releases
DXCM Income Statement
DXCM Balance Sheet
DXCM Cash Flow Statement
DXCM Long Term Solvency
Discover More
You may be interested in: